SUMMARY The possible carcinogenic effects of antisecretory agents used in the treatment of gastric and duodenal ulcer were investigated in a population based cohort study of 16 739 patients who were prescribed the H2-antagonist cimetidine between 1977 and 1981. An excess risk for gastric cancer was observed, with a relative risk of about 10 in the first year after beginning use of the drug, which decreased thereafter. A similar pattern was seen for cancers of the colon, pancreas and gall bladder, and for non-Hodgkin's lymphoma. These increased risks probably represent cases in which a malignancy was misdiagnosed as a gastric ulcer. The excess risk for gastric cancer was unaffected by the method of diagnosis, the risk in those who had undergone an endoscopy being similar to those who had been diagnosed by an x-ray examination. A relative risk of 1.5-2.0 was observed for cancer of the respiratory organs, with no effect of latency, indicating that there are common risk factors for peptic ulcer and for lung cancer. Although the observed increases in cancer risk in persons receiving cimetidine is probably caused by factors other than a carcinogenic action of the drug itself, this possibility cannot be ruled out because of the short period of follow up.
Since the introduction of H2-receptor antagonists for the treatment of gastric and duodenal ulcers, concern has been raised that their use may be accompanied by a number of side effects. Case reports have been published in which one such drug, cimetidine, was given to patients with a misdiagnosed gastric cancer, thus delaying diagnosis and perhaps reducing the possibility of radical surgical treatment."`Furthermore, the lowered gastric acidity that occurs after use of these antisecretory drugs may enhance carcinogenesis. The risk for gastric cancer has been shown to increase in patients with other conditions that result in low gastric acidity, such as persons with pernicious anaemia,4" and several large, longterm follow up studies of patients who had had a partial gastrectomy have shown an increased risk for gastric cancer after a latent period of about 20 years.`9 Gastric hypoacidity favours bacterially mediated reduction of nitrate to nitrite and formation of N-nitroso compounds.' To cimetidine is not known," " but increased concentrations of N-nitroso compounds have been shown in the gastric juice of cimetidine users" and in those with pernicious anaemia and those who have undergone a partial gastrectomy.Ẁ e describe the occurrence of cancer in a large cohort of patients who had used cimetidine during the first few years after its introduction in Table 1 . The average length of follow up was 4.5 years, and a total of 972 cases of cancer were diagnosed. The expected numbers of cancer cases were calculated by multiplying national age (five year intervals), sex, and calendar period (five year intervals) specific incidence rates by the corresponding number of personyears. Relative risks were derived by dividing the observed number of cancer cases by the expected number. One sided p values were calculated under the assumption that the observed number of cases followed a Poisson distribution to test whether the relative risks exceeded unity.
Results Tables 2 and 3 give the relative risks for cancer in men and women, respectively. The relative risk for cancer at all sites was 1 .9 in men and 1-7 in women during the first year after beginning cimetidine treatment. This risk decreased with time in both sexes. The risk for developing cancer of the digestive organs immediately after starting to use the drug was more than three times higher than that in the general population but declined gradually with time. This increased risk is accounted for mainly by the vcry high relative risks (roughly 10-fold) for cancers of the stomach and of the small intestine during the first year after start of cimetidine use in men and during the first three years in women. Ninety one per cent of the gastric cancers which occurred in the cohort were histologically verified. Increased risk of colon and pancreatic cancers were also seen immediately after starting to use cimetidine, which decreased long term.
In both men and women, excess risks for malignancies of the lymphatic and haematopoietic system were seen during the first year of follow up only. The risk for developing cancer of the respiratory organs was increased, with relative risks of about 1.5 throughout the period of follow up. Relative risks for cancer of the urinary system were increased significantly one to three years after start of cimetidine use in men and three to five years in women. A significantly raised relative risk of 1-8 was seen for cancer of the genital organs in men only in the first year of follow up.
The occurrence of gastric cancer in the cohort is further analysed in Table 4 . The excess risk is largely confined to men and women with a diagnosis of gastric ulcer, who had a 20-fold increase in the first year of follow up, which declined gradually to a relative risk of 4 8 five or more years after start of cimetidine use. The relative risk after cimetidine treatment for duodenal ulcer was increased only slightly and less so among persons followed up for more than one year. Analysis by method of diagnosis showed no striking difference between the two methods. 
Discussion
Our findings indicate that a malignant component of gastric ulcer is difficult to diagnose, because the This population based study showed a marked excess excess risk was of the same order of magnitude risk for gastric cancer and cancer of the small whether the diagnostic method used was endoscopy intestine in the first year of follow up of subjects or x-ray. No information is available on the freprescribed cimetidine as treatment for gastric ulcer. quency of biopsies and histologic examination in the We consider it highly probable that these tumours present material, and therefore it cannot be ruled out had initially been misdiagnosed as ulcers, as the that endoscopy performed by an expert and with initial symptoms of gastric cancer may resemble appropriate biopsies and histology may be superior those of gastric ulcer. to x-ray. In the present group of patients who were The potential longterm effect of cimetidine on gastric cancer risk cannot be evaluated because of the short period of follow up. The persistently increased risk was seen only in patients with gastric ulcer, which is known to develop occasionally into malignant lesions.
The excess risk for cancers of lymphatic and haematopoietic system is largely attributable to an increased risk for non-Hodgkin's lymphomas. Of a total of 25 such tumours, 15 were reported to the Danish Cancer Registry as lymphomas in the stomach (12 cases) or small intestine (three cases), whereas only 8% of all non-Hodgkin's lymphomas were reported to the Danish Cancer Registry in 1978-84 arose in those organs. Thus, lymphomas in the stomach and small intestine may also produce symptoms that resemble those of an ulcer. Increased risks for cancers at other sites in the gastrointestinal tract (colon, liver, gall bladder, pancreas) during the first year of follow up indicate similarly that the gastrointestinal discomfort caused by these conditions may have been mistaken for a gastric ulcer.
The finding of an increased risk for cancer of the respiratory system was not surprising, as tobacco smoking is casually related to ulcer and lung cancer.Ì n line with this, the increased risk was spread evenly over the period of follow up. The increased risk of cancer of the urinary system seen may also be attributable to tobacco smoking.
Colin We do not know, however, the extent to which the enrolled individuals continued to use the drug. Lack of this information will represent a problem when we evaluate the longterm effects of cimetidine, but it is of limited importance in the present context where we are concerned with cancer morbidity in the years immediately after the start of use of the drug.
In the absence of a proper control group, which would ideally have been a comparable group of untreated ulcer patients, we had to rely on national incidence rates to calculate expected numbers. The strong pattern with respect to latency seen for the excess risks for cancers of the digestive organs and of lymphatic and haematopoietic tissues, however, excludes the possibility that these effects could be the results of a selection bias.
In conclusion, a gastric ulcer patient who is prescribed cimetidine faces a 20-fold increased risk for gastric cancer within the following year, irrespective of whether the ulcer was diagnosed by endoscopy or x-ray. While our findings indicate the need for improved precision in diagnostics, the population based nature of our study can be used to put the observed increase in risk into perspective. A total of 3900 cases of gastric cancer occurred in the Danish population during the period September 1977 to July 1981. In the present material of cimetidine users, about 3% of these appear. This indicates that, in absolute terms, only a few per cent of the incident cases of gastric cancer were in fact misdiagnosed and treated as gastric ulcers. In view of the relief provided to many ulcer patients by cimetidine, this figure may be considered to be acceptable.
Whether the hypoacidic conditions produced in the stomach by cimetidine and other antisecretory drugs might lead to an increased risk of cancer can be resolved only after another 15 years of follow up of this cohort.
